Biora Therapeutics, Inc. (BIOR)
Market Cap | 23.72M |
Revenue (ttm) | 544,000 |
Net Income (ttm) | -110.86M |
Shares Out | 35.94M |
EPS (ttm) | -5.83 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 201,962 |
Open | 0.710 |
Previous Close | 0.701 |
Day's Range | 0.580 - 0.760 |
52-Week Range | 0.475 - 3.980 |
Beta | 1.24 |
Analysts | Strong Buy |
Price Target | 15.00 (+2,172.73%) |
Earnings Date | Aug 12, 2024 |
About BIOR
Biora Therapeutics, Inc., a clinical-stage biotechnology company, engages in developing oral biotherapeutics in the United States. The company offers NaviCap, a targeted oral delivery platform for delivery of therapeutics in the gastrointestinal tract to enhance the treatment of inflammatory bowel diseases; and BioJet, a systemic oral delivery platform designs to replace injection with needle-free, oral delivery of large molecules for management of chronic diseases. The company was formerly known as Progenity, Inc. and changed its name to Biora... [Read more]
Financial Performance
In 2023, BIOR's revenue was $4,000, a decrease of -98.69% compared to the previous year's $305,000. Losses were -$124.12 million, 225.3% more than in 2022.
Financial StatementsAnalyst Forecast
According to one analyst, the rating for BIOR stock is "Strong Buy" and the 12-month stock price forecast is $15.0.
News
![](https://cdn.snapi.dev/images/v1/v/k/press5-2473043.jpg)
Biora Therapeutics Announces Presentation on the BioJet™ Systemic Oral Delivery Platform at the Next Gen Peptide Formulation & Delivery Summit 2024
SAN DIEGO, June 11, 2024 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today announced that it will present preclinical dat...
![](https://cdn.snapi.dev/images/v1/3/7/press19-2439419.jpg)
Biora Therapeutics Presents Clinical Data on Device Function of the NaviCap™ Platform at Digestive Disease Week 2024
Four device performance studies demonstrate the NaviCap platform's ability to deliver therapeutics directly to the colon under variable GI conditions.
![](https://cdn.snapi.dev/images/v1/k/z/press3-2433266.jpg)
Biora Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results
Dosing of all patients in clinical trial of BT-600 has been successfully completed, with results anticipated in late Q2 2024 Clinical data on device function of the NaviCap™ platform to be presented a...
![](https://cdn.snapi.dev/images/v1/o/o/conf5-2414468.jpg)
Biora Therapeutics to Report First Quarter 2024 Financial Results and Provide Corporate Update
SAN DIEGO, May 07, 2024 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today announced it will report financial results and ...
![](https://cdn.snapi.dev/images/v1/v/d/conf15-2411761.jpg)
Biora Therapeutics to Present Clinical Data on Device Function of the NaviCap™ Oral Delivery Platform at Digestive Disease Week 2024
SAN DIEGO, May 06, 2024 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today announced that it will present clinical data on...
![](https://cdn.snapi.dev/images/v1/c/e/press16-2399537.jpg)
Biora Therapeutics Announces Completion of Multiple-Ascending Dose (MAD) Cohorts for Clinical Trial of BT-600
Dosing of all patients in the trial has been successfully completed Final results are expected to be available in late Q2 2024 SAN DIEGO, April 30, 2024 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (N...
![](https://cdn.snapi.dev/images/v1/u/g/press10-2360756.jpg)
Biora Therapeutics Announces New Patent Covering its BioJet™ Liquid Jet Delivery Technology
SAN DIEGO, April 08, 2024 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today announced the issuance of a new patent relate...
![](https://cdn.snapi.dev/images/v1/t/l/press17-2356183.jpg)
Biora Therapeutics Achieves Positive Interim Results for Clinical Trial of BT-600, Advancing NaviCap™ Platform Development
All pharmacokinetic endpoints were achieved, with a PK profile consistent with drug delivery and absorption in the colon All NaviCap™ devices performed as intended and were well tolerated, with no saf...
![](https://cdn.snapi.dev/images/v1/s/r/press7-2355207.jpg)
Biora Therapeutics Announces Closing of $6 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
SAN DIEGO, April 03, 2024 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today announced the closing of its previously annou...
![](https://cdn.snapi.dev/images/v1/h/0/press6-2349590.jpg)
Biora Therapeutics Announces $6 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
SAN DIEGO, April 01, 2024 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today announced that it has entered into definitive...
![](https://cdn.snapi.dev/images/v1/o/x/press4-2342719.jpg)
Biora Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2023 Financial Results
All performance targets achieved in single-ascending dose (SAD) cohorts of BT-600 clinical trial. Management to host conference call today at 4:30 PM ET.
![](https://cdn.snapi.dev/images/v1/i/o/conf5-2328572.jpg)
Biora Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Corporate Update
SAN DIEGO, March 18, 2024 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today announced it will report financial results an...
![](https://cdn.snapi.dev/images/v1/i/q/press19-2317610.jpg)
Biora Therapeutics Further Reduces Net Debt and Monetizes Legacy Asset
Monetization of legacy asset brings in $3 million in nondilutive capital Convertible notes exchange brings in another $2.8 million in new capital and reduces Biora's net debt SAN DIEGO, March 11, 2024...
![](https://cdn.snapi.dev/images/v1/v/q/press14-2293319.jpg)
Biora Therapeutics Announces Successful Completion of Single-Ascending Dose (SAD) Cohorts of Phase 1 Clinical Study of BT-600
Data expected to be shared during March corporate update With SAD cohorts complete, MAD cohorts to begin dosing in March SAN DIEGO, Feb. 26, 2024 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc . (Nasdaq:...
![](https://cdn.snapi.dev/images/v1/0/x/press4-2266787.jpg)
Biora Therapeutics Announces Participation in Canaccord Genuity Inflammatory Bowel Disease Symposium
SAN DIEGO, Feb. 08, 2024 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc . (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today announced it will participate in the Inflamma...
![](https://cdn.snapi.dev/images/v1/u/x/press3-2238135.jpg)
Biora Therapeutics Announces Participation in Fireside Chat Hosted by H.C. Wainwright & Co.
SAN DIEGO, Jan. 22, 2024 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today announced participation in a virtual fireside ...
![](https://cdn.snapi.dev/images/v1/j/0/press6-2230256.jpg)
Biora Therapeutics Provides Outlook for 2024
Biora anticipates 2024 catalysts, including clinical study results for NaviCap™ platform and progress on pharma partnerships for BioJet™ platform.
![](https://cdn.snapi.dev/images/v1/a/m/press19-2220016.jpg)
Biora Therapeutics Announces Initiation of Phase 1 Clinical Study of BT-600
First-in-human trial of BT-600 drug-device combination, following multiple successful device-only human studies SAD/MAD study to evaluate safety and PK/PD of BT-600, including concentrations in colon ...
![](https://cdn.snapi.dev/images/v1/6/8/press17-2213065.jpg)
Biora Therapeutics Progresses Research Collaboration for the BioJet™ Systemic Oral Delivery Platform
SAN DIEGO, Jan. 02, 2024 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today announced that its BioJet™ Systemic Oral Deliv...
![](https://cdn.snapi.dev/images/v1/o/p/press13-2201697.jpg)
Biora Therapeutics Announces New Patent for its NaviCap™ Targeted Oral Delivery Platform
SAN DIEGO, Dec. 19, 2023 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today announced that it received an Issue Notificati...
![](https://cdn.snapi.dev/images/v1/a/h/press5-2199879.jpg)
Biora Therapeutics Accelerates Debt Reduction and Raises Capital with Large Institutional Investors
Transaction results in nearly 60% reduction in net debt and brings $16 million in new capital; demonstrates investor confidence in near-term catalysts.
![](https://cdn.snapi.dev/images/v1/c/s/press5-2190905.jpg)
Biora Therapeutics Announces New Research Collaboration for the BioJet™ Systemic Oral Delivery Platform
SAN DIEGO, Dec. 11, 2023 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today announced a new research collaboration with a ...
![](https://cdn.snapi.dev/images/v1/w/z/press12-2178984.jpg)
Biora Therapeutics Announces FDA Clearance of IND Application for Drug/Device Combination BT-600 Targeting Treatment of Ulcerative Colitis
BT-600 will deliver a proprietary liquid formulation of tofacitinib via the NaviCap™ device for topical delivery to the colon SAN DIEGO, Nov. 30, 2023 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nas...
![](https://cdn.snapi.dev/images/v1/b/n/press16-2155487.jpg)
Biora Therapeutics Provides Corporate Update and Reports Third Quarter 2023 Financial Results
NaviCap™ Targeted Oral Delivery platform advancing toward initiation of phase 1 clinical trial by year end Pharma collaborations accelerate for the BioJet™ Systemic Oral Delivery platform, which shows...
![](https://cdn.snapi.dev/images/v1/m/7/conf20-2141293.jpg)
Biora Therapeutics to Report Third Quarter 2023 Financial Results and Provide Corporate Update
Biora will report financial results and provide a corporate update for the third quarter on on Monday, November 13, 2023, at 4:30 PM EST / 1:30 PM PST